Turnstone is executing an approximately 60% reduction in its workforce. The company expects that the combined efforts from the corporate reorganization and clinical program prioritization will extend cash runway into the second quarter of 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSBX:
- Turnstone Biologics announces leadership transitions
- Turnstone Biologics announces strategic prioritization of its pipeline
- Turnstone Biologics price target lowered to $10 from $12 at BofA
- Turnstone Biologics price target lowered to $3.75 from $20 at Piper Sandler
- Turnstone Biologics reports initial data from STARLING trial of TIDAL-01